KR960700069A - Wound Treatment Composition (WOUND HEALING COMPOSITION) - Google Patents

Wound Treatment Composition (WOUND HEALING COMPOSITION)

Info

Publication number
KR960700069A
KR960700069A KR1019950703140A KR19950703140A KR960700069A KR 960700069 A KR960700069 A KR 960700069A KR 1019950703140 A KR1019950703140 A KR 1019950703140A KR 19950703140 A KR19950703140 A KR 19950703140A KR 960700069 A KR960700069 A KR 960700069A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
igfbp
igf
ratio
wound
Prior art date
Application number
KR1019950703140A
Other languages
Korean (ko)
Inventor
죠지 엔. 콕스
토마스 에이. 머스토
Original Assignee
다니엘 바프네크
암겐 보울더, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다니엘 바프네크, 암겐 보울더, 인코포레이티드 filed Critical 다니엘 바프네크
Publication of KR960700069A publication Critical patent/KR960700069A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 인슐린 유사 성장인자-1과 인슐린 유사 성장인자 결합단백질로 이루어진 상처 치료용 제약 조성물에 관한 것이다. 이 제약 조성물은 비계통 적 투영요으로 제형화된다. 또한, 본 발명은 상기한 상처 치료용 조성물을 이용하는 방법에 관한 것이다.The present invention relates to a pharmaceutical composition for treating wounds comprising insulin-like growth factor-1 and insulin-like growth factor binding protein. This pharmaceutical composition is formulated with non-systemic projection. The present invention also relates to a method of using the above-described composition for treating wounds.

Description

상처 치료용 조성물(WOUND HEALING COMPOSITION)Wound Treatment Composition (WOUND HEALING COMPOSITION)

내용없음No content

Claims (18)

IGF-1 또는 그의 활성이 있는 절편과 IGFBP 또는 그의 활성이 있는 절편의 치료학적 유효량과, 제약적으로 허용가능한 담체로 이루어진 상처 치료용 제약 조성물.A pharmaceutical composition for treating wounds, comprising a therapeutically effective amount of IGF-1 or an active fragment thereof and an IGFBP or an active fragment thereof, and a pharmaceutically acceptable carrier. 제1항에 있어서, 상기 IGFBP가 IGFBP-1인 것인 제약 조성물.The pharmaceutical composition of claim 1, wherein the IGFBP is IGFBP-1. 제2항에 있어서, IGF-1대 IGFBP-1의 비율이 100:1 이하인 것인 제약 조성물.The pharmaceutical composition of claim 2, wherein the ratio of IGF-1 to IGFBP-1 is 100: 1 or less. 제3항에 있어서, IGF-1대 IGFBP-1의 비율이 1:1 내지 11:1의 범위인 것인 제약 조성물.The pharmaceutical composition of claim 3, wherein the ratio of IGF-1 to IGFBP-1 is in the range of 1: 1 to 11: 1. 제4항에 있어서, IGF-1대 IGFBP-1의 비율이 약 5:1인 것인 제약 조성물.The pharmaceutical composition of claim 4, wherein the ratio of IGF-1 to IGFBP-1 is about 5: 1. 제4항에 있어서, IGF-1대 IGFBP-1의 비율이 약 10:1인 것인 제약 조성물.The pharmaceutical composition of claim 4, wherein the ratio of IGF-1 to IGFBP-1 is about 10: 1. 제2항에 있어서, 상기 제약 조성물이 액제, 크림제, 로숀제, 겔제, 에어로졸제, 산제 또는 고형제인 것인 제약 조성물.The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition is a liquid, cream, lotion, gel, aerosol, powder or solid. 제2항에 있어서, 상기 제약 조성물이 액제인 것인 제약 조성물.The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is a liquid formulation. 상처 치료를 요하는 환자에게 제1항에 따른 제약 조성물을 베계통적으로 투여하는 것으로 이루어진, 제1항의 제약 조성물을 상처 치료에 이용하는 방법.A method of using the pharmaceutical composition of claim 1 in the treatment of wounds, which comprises routinely administering the pharmaceutical composition of claim 1 to a patient in need thereof. 제9항에 있어서, 상기 IGFBP가 IGFBP-1인 것인 방법.The method of claim 9, wherein the IGFBP is IGFBP-1. 제10항에 있어서, 상기 상기 IGFBP가 IGFBP-1인 것인 방법.The method of claim 10, wherein said IGFBP is IGFBP-1. 제10항에 있어서, 상기 제약 조성물이 국소적으로, 피내로, 직장내로, 경구로 또는 흡입에 의해 투여되는 것인 방법.The method of claim 10, wherein the pharmaceutical composition is administered topically, intradermally, rectally, orally or by inhalation. 제10항에 있어서, 상기 제약 조성물이 국소적으로 투여되는 것인 방법.The method of claim 10, wherein said pharmaceutical composition is administered topically. 제10항에 있어서, 상기 상처가 피부인 것인 방법.The method of claim 10, wherein the wound is skin. 제10항에 있어서, 상기 상처가 화상, 수술 상처, 연결 조직의 외상성 훼사, 점막의 파열, 각막 외상 또는 조직이식에 의한 상처인 것인 방법.The method of claim 10, wherein the wound is a burn, a surgical wound, a traumatic loss of connective tissue, a tear in the mucosa, a corneal trauma or a tissue transplant. 제10항에 있어서, IGF-1대 IGFBP-1의 비율이 약 5:1인 것인 방법.The method of claim 10, wherein the ratio of IGF-1 to IGFBP-1 is about 5: 1. 제10항에 있어서, IGF-1대 IGFBP-1의 비율이 1:1 내지 11:1인 것인 방법.The method of claim 10, wherein the ratio of IGF-1 to IGFBP-1 is 1: 1 to 11: 1. 제10항에 있어서, IGF-1대 IGFBP-1의 비율이 약 10:1인 것인 방법.The method of claim 10, wherein the ratio of IGF-1 to IGFBP-1 is about 10: 1. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950703140A 1993-01-29 1994-01-25 Wound Treatment Composition (WOUND HEALING COMPOSITION) KR960700069A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1103193A 1993-01-29 1993-01-29
US08/011031 1993-01-29
PCT/US1994/000799 WO1994016723A2 (en) 1993-01-29 1994-01-25 Wound healing composition

Publications (1)

Publication Number Publication Date
KR960700069A true KR960700069A (en) 1996-01-19

Family

ID=21748560

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703140A KR960700069A (en) 1993-01-29 1994-01-25 Wound Treatment Composition (WOUND HEALING COMPOSITION)

Country Status (8)

Country Link
EP (1) EP0686040A1 (en)
JP (1) JPH09500088A (en)
KR (1) KR960700069A (en)
AU (1) AU6093794A (en)
CA (1) CA2154078A1 (en)
FI (1) FI953615A (en)
NO (1) NO952987L (en)
WO (1) WO1994016723A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
DK1486565T3 (en) 1995-10-11 2008-03-10 Novartis Vaccines & Diagnostic Combination of PDGF, KGF, IGF and IGFBP for wound healing
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (en) 1999-01-06 2005-04-29 Genentech Inc VARIATION OF THE INSULIN-LIKELY GROWTH FACTOR (IGF-I)
AUPQ585500A0 (en) * 2000-02-25 2000-03-16 Gropep Pty Ltd Treatment for peripheral sensory neuropathy
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE125268T1 (en) * 1988-07-15 1995-08-15 Cent Sydney Area Health Serv ACID-SENSITIVE SUBUNIT OF AN INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN COMPLEX.
EP0546110B1 (en) * 1990-08-28 2001-11-14 Chiron Corporation New insulin-like growth factor binding protein igfbp-5
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
WO1994004030A1 (en) * 1992-08-26 1994-03-03 Celtrix Pharmaceuticals, Inc. Method for systemic treatment of catabolic conditions and systemic tissue injury

Also Published As

Publication number Publication date
JPH09500088A (en) 1997-01-07
CA2154078A1 (en) 1994-08-04
EP0686040A1 (en) 1995-12-13
WO1994016723A2 (en) 1994-08-04
AU6093794A (en) 1994-08-15
WO1994016723A3 (en) 1994-09-15
FI953615A0 (en) 1995-07-28
NO952987D0 (en) 1995-07-27
FI953615A (en) 1995-07-28
NO952987L (en) 1995-08-30

Similar Documents

Publication Publication Date Title
CA2595132C (en) Agents for controlling biological fluids and methods of use thereof
RU2129862C1 (en) Pharmaceutical composition for external using, method of treatment of wound or another body state
US8178115B2 (en) Method and composition for the treatment of scars
US8535709B2 (en) Agents for controlling biological fluids and methods of use thereof
US5583119A (en) Hyaluronic acid-urea pharmaceutical compositions and uses
US20070059350A1 (en) Agents for controlling biological fluids and methods of use thereof
US5272139A (en) Amelioration or elimination of postoperative pain
EP0673234A1 (en) Tissue protective and regenerative compositions
US5550112A (en) Hyaluronic acid-urea pharmaceutical compositions and uses
RU2106154C1 (en) Wound dressing material
KR960700069A (en) Wound Treatment Composition (WOUND HEALING COMPOSITION)
JP2983335B2 (en) Use of fosfomycin and its pharmaceutically acceptable salts as topical scar forming agents
US5024838A (en) Compositions for the treatment of skin injuries
ES2312421T3 (en) PHARMACEUTICAL COMPOSITION IN GEL.
US20030170225A1 (en) Method of enhancing the effect of collagenase on wounds
JPH01279840A (en) Novel composition for external use
JPH07215894A (en) Wound-healing agent
RU2115424C1 (en) Agent and a method of stimulation of reparative regeneration
CA1300505C (en) Amelioration or elimination of postoperative pain
RU2063752C1 (en) Medicinal agent for treatment of senile, diabetic and radiation sluggish wound
RU2144816C1 (en) Wound-healing composition "lesta"
Ludwig The use of saline solution, glycerin, and acetic acid in the care of burns: An odorless method of treating burns
RU95105265A (en) Agent for treatment of trophic ulcers and burns in patients with leprosy
CN1399967A (en) Wound healing ointment
RU93031950A (en) PREPARATION FOR TREATMENT OF THE RAS

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid